Drugs / GSK315234
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00674635 Comparator | Apr 2008 → Dec 2010 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK315234 | “An exploratory analysis of clinical, pharmacokinetic and pharmacodynamics data suggests the lack of efficacy may be due to moderate binding affinity and rapid off-rate of...” PMID 24286335 ↗ Sep 2013 |
| Action | Inhibit | “Our data highlighted the importance of binding affinity and off-rate effect of a mAb to fully neutralize the target” PMID 24286335 ↗ Sep 2013 |
| Modality | Monoclonal antibody | “Using an anti-OSM mAb with high affinity should test this hypothesis and examine the potential of OSM as a therapeutic target in RA.” PMID 24286335 ↗ Sep 2013 |
| Route | Intravenous | “single and repeat intravenous infusions” NCT00674635 ↗ |
| Target | OSM | “Using an anti-OSM mAb with high affinity should test this hypothesis and examine the potential of OSM as a therapeutic target in RA.” PMID 24286335 ↗ Sep 2013 |